Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT05252416 Recruiting - Ovarian Cancer Clinical Trials

(VELA) Study of BLU-222 in Advanced Solid Tumors

Start date: April 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.

NCT ID: NCT05240898 Recruiting - Clinical trials for Advanced Solid Tumors

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

Start date: August 16, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.

NCT ID: NCT05234853 Recruiting - Clinical trials for Advanced Solid Tumors

Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors

Start date: April 28, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I, First-In-Human, open label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of PUR001, an anti-CD39 monoclonal antibody, in adult patients with advanced solid tumors, as monotherapy. A "3+3" design will be used to determine MTD and RP2D. .

NCT ID: NCT05233436 Terminated - Gastric Cancer Clinical Trials

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Start date: February 24, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate the clinical activity of monotherapy and combination; and select the recommended dose of PF-07265028 monotherapy and in combination for potential further studies and development. The study contains 2 parts, Dose Escalation (Part 1) to determine the recommended dose of PF-07265028 as single agent and in combination, followed by Dose Expansion (Part 2) in selected tumor types at the recommended dose. It is expected that most participants will take part in this study for up to 1 year with six on-site visits in the first month and then at least twice every subsequent month while they are on treatment.

NCT ID: NCT05214976 Enrolling by invitation - Clinical trials for Advanced Solid Tumors

A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Start date: August 12, 2022
Phase: Phase 2
Study type: Interventional

The study is being conducted to evaluate safety, tolerability and preliminary efficacy of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) for advanced solid tumors of patients. To explore the reasonable dosage of dosage regimen of combination therapy for advanced malignant tumors of patients.

NCT ID: NCT05194709 Recruiting - Clinical trials for Advanced Solid Tumors

Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors

Start date: December 30, 2021
Phase: Early Phase 1
Study type: Interventional

This study is an interventional, single arm, open-label, investigator-initiated trial (IIT) to evaluate the safety, tolerability, initial efficacy and pharmacokinetics (PK) of anti-5T4 CAR-NK cells in patients with advanced solid tumors.

NCT ID: NCT05172856 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Start date: March 1, 2022
Phase: Phase 1
Study type: Interventional

This is open-label, multicenter, Phase Ib study is designed to evaluate the Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in participants with advanced solid tumors.

NCT ID: NCT05171790 Active, not recruiting - Clinical trials for Advanced Solid Tumors

A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors

Start date: January 11, 2021
Phase: Phase 1
Study type: Interventional

This a multi-center, open-label, non-randomized phaseⅠb trail. The purpose of this study was to evaluate the efficacy and safety of QL1706 in patients with advanced solid tumors and to investigate the immunogenicity and pharmacokinetic characteristics of QL1706.

NCT ID: NCT05164458 Recruiting - Clinical trials for Advanced Solid Tumors

Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies

Start date: March 22, 2022
Phase: Phase 1
Study type: Interventional

This study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of IBI389 as a single agent, and in combination with sintilimab, and (or) chemotherapy in patients with advanced or metastatic solid tumors.

NCT ID: NCT05153096 Not yet recruiting - Clinical trials for Advanced Solid Tumors

Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors

Start date: April 2022
Phase: Phase 1
Study type: Interventional

This trial is an open-label, multicenter, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors. The aim of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of NBL-015 in patients with advanced solid tumors.